Does BCBS North Carolina cover Wegovy?

It depends on your benefits. BCBS North Carolina covers Wegovy for heart disease risk reduction only when your plan includes that benefit and the policy requirements are met.

How long does a Wegovy approval last with BCBS North Carolina?

Heart Disease Risk Reduction — Applies to Employer plans. Initial approval: 6 months. Renewal: every 12 months.

What does BCBS North Carolina require to renew Wegovy?

Heart Disease Risk Reduction — Applies to Employer plans. Patient must continue optimized pharmacotherapy for established CVD in combination with Wegovy AND demonstrate a positive clinical response. Initial CVD, BMI, and GDMT requirements are re-verified at continuation for this indication.

How current is this information?

The oldest review date among the policies on this page is July 16, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

BCBS North Carolina coverage for Wegovy (Heart

Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Patient must have anti-obesity medication coverage benefits (criterion 7 of initial criteria; criterion 4 of continuation criteria)

Qualification pathways

You can qualify through any one of these.

CV risk reduction — established cardiovascular disease with qualifying event

All of:

Patient is 18 years of age or older
Using medication to reduce risk of MACE (cardiovascular death, non-fatal MI, or non-fatal stroke)
Established cardiovascular disease (defined as: CAD, ACS, history of MI, stable or unstable angina, coronary or other arterial revascularization, prior PCI/CABG, stroke, TIA, carotid or other arterial stenosis, or PAD including aortic aneurysm, all of atherosclerotic origin)
BMI ≥ 27 kg/m2
Patient will use optimized pharmacotherapy for established cardiovascular disease in combination with Wegovy
Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
Requested medication will NOT be used concurrently with another weight loss medication
Patient has anti-obesity medication coverage benefits

Plus any one of:

History of myocardial infarction
History of stroke
Peripheral artery disease defined by intermittent claudication with ankle-brachial index < 0.85 at rest, peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

Documentation to bring

Documentation of established cardiovascular disease (CAD, ACS, MI, angina, revascularization, PCI/CABG, stroke, TIA, carotid/arterial stenosis, or PAD of atherosclerotic origin)
Documentation of qualifying CV event history (MI, stroke, or PAD with ABI < 0.85, revascularization, or amputation)
Baseline BMI ≥ 27 kg/m2
Documentation of current use of optimized pharmacotherapy for established cardiovascular disease or clinical reason it is not appropriate
Documentation that patient is not concurrently using another GLP-1 receptor agonist
Documentation that patient is not concurrently using another weight loss medication
Confirmation of anti-obesity medication coverage benefits

Quantity limits

0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL — 4 pens per 28 days
1.5 mg tablet — 1 tablet per day
4 mg tablet — 1 tablet per day
9 mg tablet — 1 tablet per day

Approval and renewal

Initial approval: 6 months
Renewal: every 12 months
Renewal: Patient must continue optimized pharmacotherapy for established CVD in combination with Wegovy AND demonstrate a positive clinical response. Initial CVD, BMI, and GDMT requirements are re-verified at continuation for this indication.

Not covered when

Concurrent use of another GLP-1 receptor agonist
Concurrent use of another weight loss medication

Policy note: Applies to both Wegovy injection (0.25mg–2.4mg) and Wegovy tablets. CV risk reduction indication requires established CVD with at least one specific qualifying event (MI, stroke, or PAD) plus BMI ≥ 27. 'Optimized pharmacotherapy' is not further specified in the policy. Excludes diabetes is false — the policy does not exclude diabetic patients from this indication. Definition of established CVD was added June 2025.

Policy effective July 1, 2026 · verified July 16, 2026 · source: BCBS North Carolina Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Open on its own page →

If heart disease risk reduction isn't covered on your plan

A prior authorization can't override a benefit exclusion. Ask BCBS North Carolina about a formulary exception.

Questions people ask

Does BCBS North Carolina cover Wegovy?: It depends on your benefits. BCBS North Carolina covers Wegovy for heart disease risk reduction only when your plan includes that benefit and the policy requirements are met.
How long does a Wegovy approval last with BCBS North Carolina?: Heart Disease Risk Reduction — Applies to Employer plans. Initial approval: 6 months. Renewal: every 12 months.
What does BCBS North Carolina require to renew Wegovy?: Heart Disease Risk Reduction — Applies to Employer plans. Patient must continue optimized pharmacotherapy for established CVD in combination with Wegovy AND demonstrate a positive clinical response. Initial CVD, BMI, and GDMT requirements are re-verified at continuation for this indication.
How current is this information?: The oldest review date among the policies on this page is July 16, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Does BCBS North Carolina cover Wegovy for Heart Disease Risk Reduction?

Policy document